NO20015065D0 - Pyrazolobenzodiazepiner som CDK2-inhibitorer - Google Patents

Pyrazolobenzodiazepiner som CDK2-inhibitorer

Info

Publication number
NO20015065D0
NO20015065D0 NO20015065A NO20015065A NO20015065D0 NO 20015065 D0 NO20015065 D0 NO 20015065D0 NO 20015065 A NO20015065 A NO 20015065A NO 20015065 A NO20015065 A NO 20015065A NO 20015065 D0 NO20015065 D0 NO 20015065D0
Authority
NO
Norway
Prior art keywords
pyrazolobenzodiazepines
cdk2 inhibitors
cdk2
inhibitors
Prior art date
Application number
NO20015065A
Other languages
English (en)
Norwegian (no)
Other versions
NO20015065L (no
Inventor
Qingjie Ding
Jin-Jun Liu
Vincent Stewart Madison
Giacomo Pizzolato
Chung-Chen Wei
Peter Michael Wovkulich
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20015065D0 publication Critical patent/NO20015065D0/no
Publication of NO20015065L publication Critical patent/NO20015065L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/22—Sulfur atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
NO20015065A 1999-04-21 2001-10-18 Pyrazolobenzodiazepiner som CDK2-inhibitorer NO20015065L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13037099P 1999-04-21 1999-04-21
PCT/EP2000/003394 WO2000064900A1 (en) 1999-04-21 2000-04-14 Pyrazolobenzodiazepines as cdk2 inhibitors

Publications (2)

Publication Number Publication Date
NO20015065D0 true NO20015065D0 (no) 2001-10-18
NO20015065L NO20015065L (no) 2001-10-18

Family

ID=22444382

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20015065A NO20015065L (no) 1999-04-21 2001-10-18 Pyrazolobenzodiazepiner som CDK2-inhibitorer

Country Status (33)

Country Link
US (3) US6440959B1 (sh)
EP (1) EP1185529B1 (sh)
JP (1) JP3746680B2 (sh)
KR (1) KR100481757B1 (sh)
CN (2) CN1279029C (sh)
AR (1) AR023542A1 (sh)
AT (1) ATE279413T1 (sh)
AU (1) AU768667B2 (sh)
BR (1) BR0009887A (sh)
CA (1) CA2367704C (sh)
CO (1) CO5170444A1 (sh)
CZ (1) CZ20013738A3 (sh)
DE (1) DE60014893T2 (sh)
DK (1) DK1185529T3 (sh)
ES (1) ES2228522T3 (sh)
HK (1) HK1046278B (sh)
HR (1) HRP20010742A2 (sh)
HU (1) HUP0300318A3 (sh)
IL (1) IL145764A0 (sh)
JO (1) JO2248B1 (sh)
MA (1) MA26782A1 (sh)
NO (1) NO20015065L (sh)
NZ (1) NZ514523A (sh)
PE (1) PE20010054A1 (sh)
PL (1) PL200933B1 (sh)
PT (1) PT1185529E (sh)
RU (1) RU2249593C2 (sh)
SI (1) SI1185529T1 (sh)
TR (1) TR200103016T2 (sh)
TW (1) TW585866B (sh)
WO (1) WO2000064900A1 (sh)
YU (1) YU73101A (sh)
ZA (1) ZA200108016B (sh)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2309209T3 (es) * 2001-11-13 2008-12-16 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. 1,4-benzodiazepinas sustituidas y uso de las mismas para el tratamiento del cancer.
FR2847253B1 (fr) * 2002-11-19 2007-05-18 Aventis Pharma Sa Nouveaux derives de pyridazinones a titre de medicaments et compositions pharmaceutiques les renfermant
BRPI0407841A (pt) * 2003-02-27 2006-11-14 Abbott Lab inibidores heterocìclicos de quinase
ATE398619T1 (de) * 2004-10-13 2008-07-15 Hoffmann La Roche Als cdk2- und angiogenese-inhibitoren und für die behandlung von brust-, kolon-, lungen- und prostatakrebs geeignete disubstituierte pyrazolobenzodiazepine
KR20110010813A (ko) * 2005-10-14 2011-02-07 에프. 호프만-라 로슈 아게 5-(2-클로로페닐)-1,2-디히드로-7-플루오로-8-메톡시-3-메틸-피라졸로[3,4-ｂ][1,4] 벤조디아제핀의 투여 섭생
MX2009000404A (es) 2006-07-10 2009-06-26 Paion Uk Ltd Sales de benzodiazepina de accion corta y sus formas polimorficas.
KR20100073454A (ko) * 2008-12-23 2010-07-01 국립암센터 트란스글루타미나제 억제제로 사용되는 신규한 피라졸로디아제핀계 화합물, 이의 제조방법 및 이를 포함하는 조성물
EP2305647A1 (en) 2009-09-18 2011-04-06 PAION UK Limited Process for preparing 3-[(4S)-8-bromo-1-methyl-6-(2-pyridinyl)-4 H-imidazo[1,2-a][1,4]benzodiazepine-4-yl] propionic acid methyl ester or the benzene sulfonate salt thereof, and compounds useful in that process
EP2450039A1 (en) 2010-11-08 2012-05-09 PAION UK Ltd. Dosing regimen for sedation with CNS 7056 (Remimazolam)
WO2013116786A1 (en) * 2012-02-02 2013-08-08 Senex Biotechnology Inc. Cdk8/cdk19 selective inhibitors and their use in anti-metastatic and chemopreventative methods for cancer
CN102603743B (zh) * 2012-02-24 2014-05-28 南京天易生物科技有限公司 抗肿瘤的氮杂苯并[f]薁衍生物其制备方法及其用途
CN103288830A (zh) * 2012-02-24 2013-09-11 中国科学院大连化学物理研究所 一种合成手性二氢-5H-吡咯并[2,1-c][1,4]-苯并二氮杂卓的方法
CN103288828A (zh) * 2012-02-24 2013-09-11 中国科学院大连化学物理研究所 一种合成手性二氢-6H-吲哚并[2,1-c][1,4]-苯并二氮杂卓的方法
AR094963A1 (es) 2013-03-04 2015-09-09 Ono Pharmaceutical Co Reacción de oxidación excelente en el índice de conversión
CN106608877B (zh) * 2015-10-21 2018-11-13 新发药业有限公司 一种依鲁替尼中间体4-氨基-3-（4-苯氧基）苯基-1H-吡唑并[3,4-d]嘧啶的制备方法
WO2018083051A1 (en) * 2016-11-01 2018-05-11 F. Hoffmann-La Roche Ag 1,3-dihydro-1,4-benzodiazepine-2-thiones for the treatment of cns related diseases
CA3041155C (en) * 2016-12-13 2021-12-14 Nanjing Transthera Biosciences Co., Ltd. Multi-kinase inhibitor compound, and crystal form and use thereof
CN109020980B (zh) * 2017-06-09 2020-11-20 华东师范大学 一类抗肿瘤作用的吡唑并嘧啶二氮*衍生物
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
WO2020180959A1 (en) 2019-03-05 2020-09-10 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
US11919904B2 (en) 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors
WO2020223558A1 (en) * 2019-05-01 2020-11-05 Incyte Corporation Tricyclic amine compounds as cdk2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
TW202115024A (zh) 2019-08-14 2021-04-16 美商英塞特公司 作為cdk2 抑制劑之咪唑基嘧啶基胺化合物
US11851426B2 (en) 2019-10-11 2023-12-26 Incyte Corporation Bicyclic amines as CDK2 inhibitors
EP4148054A4 (en) * 2020-05-08 2024-06-05 Transthera Sciences (Nanjing), Inc. SYNTHESIS PROCESS FOR ANTI-TUMOOR COMPOUND AND INTERMEDIATE PRODUCT THEREOF
AR124154A1 (es) 2020-11-27 2023-02-22 Rhizen Pharmaceuticals Ag Inhibidores de cdk
WO2022149057A1 (en) 2021-01-05 2022-07-14 Rhizen Pharmaceuticals Ag Cdk inhibitors
MX2023013173A (es) 2021-05-07 2023-11-30 Kymera Therapeutics Inc Degradadores de cinasa 2 dependiente de ciclina (cdk2) y sus usos.
WO2022237765A1 (zh) * 2021-05-10 2022-11-17 药捷安康(南京)科技股份有限公司 多激酶抑制剂的药物组合物及其用途
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
WO2024030399A2 (en) * 2022-08-02 2024-02-08 Lab1636, Llc Use of a gaba-a pam for reduction of tactile hypersensitivity

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE291022T1 (de) 1996-10-02 2005-04-15 Novartis Pharma Gmbh Pyrimiderivate und verfahren zu ihrer herstellung
US6350786B1 (en) * 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers

Also Published As

Publication number Publication date
CN1603314A (zh) 2005-04-06
CN1279029C (zh) 2006-10-11
PL200933B1 (pl) 2009-02-27
AU4748000A (en) 2000-11-10
TR200103016T2 (tr) 2002-04-22
PE20010054A1 (es) 2001-02-07
PL354405A1 (en) 2004-01-12
ES2228522T3 (es) 2005-04-16
HK1046278A1 (en) 2003-01-03
BR0009887A (pt) 2002-01-22
CA2367704A1 (en) 2000-11-02
ZA200108016B (en) 2003-03-26
JP3746680B2 (ja) 2006-02-15
TW585866B (en) 2004-05-01
CN1348455A (zh) 2002-05-08
US6838558B2 (en) 2005-01-04
HUP0300318A2 (hu) 2003-06-28
CA2367704C (en) 2008-06-17
AU768667B2 (en) 2003-12-18
MA26782A1 (fr) 2004-12-20
CN1196703C (zh) 2005-04-13
WO2000064900A1 (en) 2000-11-02
AR023542A1 (es) 2002-09-04
HRP20010742A2 (en) 2002-12-31
US6916923B2 (en) 2005-07-12
DE60014893T2 (de) 2005-10-13
CO5170444A1 (es) 2002-06-27
HUP0300318A3 (en) 2004-11-29
NO20015065L (no) 2001-10-18
DE60014893D1 (de) 2004-11-18
RU2249593C2 (ru) 2005-04-10
PT1185529E (pt) 2005-02-28
EP1185529B1 (en) 2004-10-13
JO2248B1 (en) 2004-10-07
HK1046278B (zh) 2005-08-12
JP2002543081A (ja) 2002-12-17
ATE279413T1 (de) 2004-10-15
YU73101A (sh) 2004-05-12
SI1185529T1 (en) 2005-02-28
US6440959B1 (en) 2002-08-27
US20020183514A1 (en) 2002-12-05
EP1185529A1 (en) 2002-03-13
CZ20013738A3 (cs) 2002-08-14
US20040198976A1 (en) 2004-10-07
KR100481757B1 (ko) 2005-04-11
DK1185529T3 (da) 2005-02-07
IL145764A0 (en) 2002-07-25
KR20010112435A (ko) 2001-12-20
NZ514523A (en) 2003-11-28

Similar Documents

Publication Publication Date Title
NO20015065L (no) Pyrazolobenzodiazepiner som CDK2-inhibitorer
NO20021239D0 (no) Pteridinoner som kinase-inhibitorer
DK1244647T3 (da) Quinzolinderivater som VIGF-inhibitorer
DK2253620T3 (da) Substituerede 3-cyanoquinoliner som protein-tyrosinkinase-inhibitorer
NO20023828L (no) Pyrimidin-4-on derivater som LDL-PLA2 inhibitorer
PT1181017E (pt) Inibidores de metaloproteases
NO20031006L (no) Imidazolo-5-yl-2-anilino-pyrimidiner som midler for inhibering av celleproliferasjon
NO20014642L (no) Aminopyrimidiner som sorbitol-dehydrogenase-inhibitorer
ATE295848T1 (de) C-aryl-glucosid-sglt2-inhibitoren
NO20021329D0 (no) Kinaseinhibitorer som terapeutiske midler
DK1140840T3 (da) omega-carboxyaryl-substituerede diphenylurinstoffer som raf-kinase-inhibitorer
EE200100492A (et) Ensüümi IMPDH inhibiitorid
NO20030867L (no) Hydroksamderivater anvendelig som deacetylaseinhibitorer
PT1194404E (pt) Inibidores de aspartil-protease
NO20024997D0 (no) 2-guanidino-4-arylkinazoliner som NHE-3-inhibitorer
DK1272488T3 (da) Tri-aryl-substitueret ethan-PDE4-inhibitorer
NO20016201D0 (no) Tienopyrimidiner som fosfodiesteraseinhibitorer
NO20014243D0 (no) Dihetero-substituerte metalloprotease inhibitorer
NO20021959D0 (no) Tetrahydrotiopyranftalazinon-derivater som PDE4-inhibitorer
NO20015247D0 (no) Glysinspaltingssysteminhibitorer som potensielle antipsykotika
NO20014875L (no) Promedikamenter for trombin inhibitorer
DE60024101D1 (de) Enzyminhibitoren
DE60009260D1 (de) Thiopyranderivate as mmp-inhibitoren
DK1487802T3 (da) 2,3-diaryl-pyrazolidin-derivater som neurotensin-nedbrydende enzyminhibitorer
DK1380585T3 (da) Pyrazolopyridinon som mellemprodukt

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application